Treatment of engrafted mice with the SMO inhibitor vismodegib reduced immunosuppressive immune cell populations such as MDSCs, M2 macrophages and Treg cells in the tumor lesions, while it increased the number of cytotoxic CD8+ T-cells and M1 macrophages, resulting in less metastasis. This evidence concerns the gene SMO and neoplasm.